Safety, Pharmacokinetics (PK) and Efficacy of AI-061, A 1:1 Co-formulation of AI-025 (Anti-PD-1) and ONC-392 (Anti-CTLA-4) Antibodies in Advanced Solid Tumors: An Open-Label Phase 1 Study
NCT05858736 · ACTIVE NOT RECRUITING · Phase 1
We track 1 ClinicalTrials.gov studies led by Oncoc4 Inc. The portfolio skews toward Phase 1 (1 trials).
1 clinical trials sponsored by Oncoc4 Inc.
| Phase | Trials | Distribution |
|---|---|---|
| Phase 1 | 1 | 100% |
Oncoc4 Inc currently sponsors 1 clinical trials tracked on ReadTheTrial. These span Phase 1.
Oncoc4 Inc conducts research across multiple therapeutic areas. Browse the trial listings for details.
Check the trial listings below for current recruitment status. Trial recruitment status can change frequently.